

37W

CT2779 US - NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Loriann Kazmercyk  
Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
October 19, 2005  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF  
**RICHARD COLONNO, ET AL.**  
APPLICATION NO: **10/637,156**  
FILED: **08/08/2003**  
FOR: **COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV**  
**REPLICATION**

ART UNIT: **1648**  
EXAMINER: **BROWN, TIMOTHY M**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding PCT International application. Copies of the references and the search report are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.


Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ. 08543-4000

Date: *October 19, 2005*

  
\_\_\_\_\_  
Warren, K. Volles  
Attorney for Applicant  
Reg. No. 33,810  
Phone: 203-677-6997

**SIDS October 2005**



SIDS October 2005

PTO/SB/08B (8/03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

**COMPLETE IF KNOWN**

Application Number	10/637156
Filing Date	08/08/2003
First Named Inventor	RICHARD COLONNO
Art Unit	1648
Examiner Name	BROWN, TIMOTHY M
Attorney Docket Number	CT2779-US - NP

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	SARRAZIN, C. et al., "Mutations in the Protein Kinase-Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response," The Journal of Infectious Diseases, Vol. 181, pp. 432-441 (2000)	
	2AB	FRANGEUL, L. et al., "Mutations in NS5A Region of Hepatitis C Virus Genome Correlate With Presence of NS5A Antibodies and Response to Interferon Therapy for Most Common European Hepatitis C Virus Genotypes," Hepatology, Vol. 28, No. 6, pp. 1674-1679 (1998)	
	2AC	WOITAS, R.P. et al., "Differential expansion of T-cell receptor variable beta subsets after antigenic stimulation in patients with different outcomes of hepatitis C infection," Immunology, Vol. 106, pp. 419-427 (2002)	
	2AD	WANG, Y.S. et al., "Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications," Advanced Drug Delivery Reviews, Vol 54, pp. 547-570 (2002)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant